Craft

Pulse Biosciences

Stock Price

$17

2024-10-29

Market Capitalization

$1 B

2024-10-29

Revenue

$350 K

FY, 2025

Pulse Biosciences Summary

Company Summary

Overview
Pulse Biosciences is a medical technology company developing a novel tissue treatment platform based on its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation is a non-thermal, precise, focal drug-free tissue treatment technology that initiates cell death within treated tissue. NPS utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles. Once created, these transient nanopores allow ions to pass through these membranes, which disrupts cellular function and initiates cell death. NPS cell death eliminates treated tissue cells with a minimal inflammatory response, leading to a favorable healing process and the replacement of treated tissue cells with healthy tissue cells.
Type
Public
Status
Active
Founded
2014
HQ
Hayward, CA, US | view all locations
Website
http://www.pulsebiosciences.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Darrin R Uecker

    Darrin R Uecker, Chief Executive Officer, President and Director

  • Ed Ebbers, Executive Vice President and General Manager, Dermatology

  • Laureen Debuono, Director

    • Richard Nuccitelli, Chief Science Officer

    Operating MetricsView all

    Patents Issued

    49

    FY, 2016

    Patent Applications

    61

    FY, 2016

    LocationsView all

    1 location detected

    • Hayward, CA HQ

      United States

      3957 Point Eden Way

    Pulse Biosciences Financials

    Summary Financials

    Revenue (Q1, 2026)
    $401.0K
    Gross profit (Q1, 2026)
    $31.0K
    Net income (Q1, 2026)
    ($18.6M)
    Cash (Q1, 2026)
    $68.3M
    EBIT (Q1, 2026)
    ($19.2M)
    Enterprise value
    $983.2M

    Footer menu